PDIA5 and cancer: Since our study regarding the correlations between PDIA5 expression and drug sensitivity of cancer cell lines was predictive research based on existing databases, there is no available information linking the PDIA5 overexpression in these types of cancer and resistance to PAC-1, teniposide, tozasertib, KIN001-102, and GSK1070916 treatment.